Tearsheet

InnovAge (INNV)


Market Price (5/23/2026): $7.185 | Market Cap: $975.0 Mil
Sector: Health Care | Industry: Health Care Facilities

InnovAge (INNV)


Market Price (5/23/2026): $7.185
Market Cap: $975.0 Mil
Sector: Health Care
Industry: Health Care Facilities

Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.

0

Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care.

Weak multi-year price returns
3Y Excs Rtn is -67%

Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -4.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.5%

Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.3%

Key risks
INNV key risks include [1] a documented history of regulatory sanctions for compliance failures, Show more.

0 Megatrend and thematic drivers
Megatrends include Aging Population & Chronic Disease. Themes include Geriatric Care.
1 Weak multi-year price returns
3Y Excs Rtn is -67%
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -4.5 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -0.5%
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -5.3%
4 Key risks
INNV key risks include [1] a documented history of regulatory sanctions for compliance failures, Show more.

Valuation, Metrics & Events

Price Chart

Why The Stock Moved

Qualitative Assessment

AI Analysis | Feedback

InnovAge (INNV) stock has gained about 30% since 1/31/2026 because of the following key factors:

1. InnovAge experienced a significant improvement in its financial performance during the fiscal second quarter ended December 31, 2025, reported on February 3, 2026. The company reported total revenues of $239.7 million, a 14.7% increase compared to the prior-year quarter. Crucially, InnovAge achieved a net income of $11.8 million, a notable turnaround from a net loss of $13.5 million in Q2 Fiscal Year 2025. Adjusted EBITDA also saw a substantial rise to $22.2 million from $5.9 million in the same period, reaching a 9.2% margin and meeting its intermediate-term target. This strong performance led the company to raise its full-year fiscal 2026 guidance, projecting total revenue between $925 million and $950 million and Adjusted EBITDA between $70 million and $75 million.

2. The company demonstrated continued operational momentum with strong revenue growth and a further increase in its full-year fiscal 2026 guidance during the fiscal third quarter ended March 31, 2026, reported on May 5, 2026. InnovAge posted total revenues of $251.9 million, an increase of approximately 15.5% year-over-year. Adjusted EBITDA rose to $30.5 million, marking an increase of $19.7 million compared to Q3 Fiscal Year 2025. The center-level contribution margin also improved to 24.2%. Reflecting this sustained positive trend, the company again raised its full-year fiscal 2026 guidance, now expecting revenue between $950 million and $975 million and Adjusted EBITDA between $85 million and $90 million. This positive outlook was a core reason for investor confidence, even as the company reported a wider net loss of $29.9 million for the quarter, largely attributed to higher legal and litigation expenses.

Show more
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →

Stock Movement Drivers

Fundamental Drivers

The 29.7% change in INNV stock from 1/31/2026 to 5/22/2026 was primarily driven by a 21.0% change in the company's P/S Multiple.
(LTM values as of)13120265222026Change
Stock Price ($)5.557.2029.7%
Change Contribution By: 
Total Revenues ($ Mil)8859497.3%
P/S Multiple0.91.021.0%
Shares Outstanding (Mil)136136-0.1%
Cumulative Contribution29.7%

LTM = Last Twelve Months as of date shown

Market Drivers

1/31/2026 to 5/22/2026
ReturnCorrelation
INNV29.7% 
Market (SPY)8.1%19.1%
Sector (XLV)-2.7%36.2%

Fundamental Drivers

The 60.4% change in INNV stock from 10/31/2025 to 5/22/2026 was primarily driven by a 44.8% change in the company's P/S Multiple.
(LTM values as of)103120255222026Change
Stock Price ($)4.497.2060.4%
Change Contribution By: 
Total Revenues ($ Mil)85494911.2%
P/S Multiple0.71.044.8%
Shares Outstanding (Mil)135136-0.4%
Cumulative Contribution60.4%

LTM = Last Twelve Months as of date shown

Market Drivers

10/31/2025 to 5/22/2026
ReturnCorrelation
INNV60.4% 
Market (SPY)9.9%5.5%
Sector (XLV)4.8%28.9%

Fundamental Drivers

The 130.0% change in INNV stock from 4/30/2025 to 5/22/2026 was primarily driven by a 95.9% change in the company's P/S Multiple.
(LTM values as of)43020255222026Change
Stock Price ($)3.137.20130.0%
Change Contribution By: 
Total Revenues ($ Mil)80794917.7%
P/S Multiple0.51.095.9%
Shares Outstanding (Mil)135136-0.2%
Cumulative Contribution130.0%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2025 to 5/22/2026
ReturnCorrelation
INNV130.0% 
Market (SPY)36.0%22.4%
Sector (XLV)8.6%29.4%

Fundamental Drivers

The 17.8% change in INNV stock from 4/30/2023 to 5/22/2026 was primarily driven by a 37.8% change in the company's Total Revenues ($ Mil).
(LTM values as of)43020235222026Change
Stock Price ($)6.117.2017.8%
Change Contribution By: 
Total Revenues ($ Mil)68994937.8%
P/S Multiple1.21.0-14.4%
Shares Outstanding (Mil)136136-0.1%
Cumulative Contribution17.8%

LTM = Last Twelve Months as of date shown

Market Drivers

4/30/2023 to 5/22/2026
ReturnCorrelation
INNV17.8% 
Market (SPY)86.3%24.1%
Sector (XLV)18.0%26.9%

Return vs. Risk

Price Returns Compared

 202120222023202420252026Total [1]
Returns
INNV Return-79%44%-16%-34%32%42%-70%
Peers Return39%2%18%13%21%2%134%
S&P 500 Return27%-19%24%23%16%9%98%

Monthly Win Rates [3]
INNV Win Rate30%67%67%33%42%60% 
Peers Win Rate63%53%57%53%62%32% 
S&P 500 Win Rate75%42%67%75%67%60% 

Max Drawdowns [4]
INNV Max Drawdown--48%-35%-44%-34%-33% 
Peers Max Drawdown-22%-37%-25%-31%-30%-26% 
S&P 500 Max Drawdown-5%-25%-10%-8%-19%-9% 


[1] Cumulative total returns since the beginning of 2021
[2] Peers: ACHC, HCA, THC, ENSG, UHS.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 5/22/2026 (YTD)

How Low Can It Go

EventINNVS&P 500
2025 US Tariff Shock
  % Loss-21.6%-18.8%
  % Gain to Breakeven27.6%23.1%
  Time to Breakeven30 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-28.6%-9.5%
  % Gain to Breakeven40.0%10.5%
  Time to Breakeven826 days24 days
2023 SVB Regional Banking Crisis
  % Loss-25.2%-6.7%
  % Gain to Breakeven33.6%7.1%
  Time to Breakeven42 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-30.1%-24.5%
  % Gain to Breakeven43.1%32.4%
  Time to Breakeven9 days427 days

Compare to ACHC, HCA, THC, ENSG, UHS

In The Past

InnovAge's stock fell -21.6% during the 2025 US Tariff Shock. Such a loss loss requires a 27.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

EventINNVS&P 500
2025 US Tariff Shock
  % Loss-21.6%-18.8%
  % Gain to Breakeven27.6%23.1%
  Time to Breakeven30 days79 days
Summer-Fall 2023 Five Percent Yield Shock
  % Loss-28.6%-9.5%
  % Gain to Breakeven40.0%10.5%
  Time to Breakeven826 days24 days
2023 SVB Regional Banking Crisis
  % Loss-25.2%-6.7%
  % Gain to Breakeven33.6%7.1%
  Time to Breakeven42 days31 days
2022 Inflation Shock & Fed Tightening
  % Loss-30.1%-24.5%
  % Gain to Breakeven43.1%32.4%
  Time to Breakeven9 days427 days

Compare to ACHC, HCA, THC, ENSG, UHS

In The Past

InnovAge's stock fell -21.6% during the 2025 US Tariff Shock. Such a loss loss requires a 27.6% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About InnovAge (INNV)

InnovAge Holding Corp. manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities. It manages its business through Program of All-Inclusive Care for the Elderly (PACE) approach. The company offers in-home care services consisting of skilled, unskilled, and personal care; in-center services, such as primary care, physical therapy, occupational therapy, speech therapy, dental services, mental health and psychiatric services, meals, and activities; transportation to the PACE center and third-party medical appointments; and care management. It serves approximately 6,850 PACE participants in the United States; and operates 18 PACE centers in Colorado, California, New Mexico, Pennsylvania, and Virginia. The company was formerly known as TCO Group Holdings, Inc. and changed its name to InnovAge Holding Corp. in January 2021. InnovAge Holding Corp. was founded in 2007 and is headquartered in Denver, Colorado.

AI Analysis | Feedback

Kaiser Permanente for seniors, but focused on keeping them independent in their homes and communities.

A 'one-stop-shop' like Sam's Club or Costco, but for all the medical, social, and daily living needs of seniors who want to live independently at home.

AI Analysis | Feedback

  • Program of All-Inclusive Care for the Elderly (PACE): An integrated healthcare model that provides comprehensive medical and ancillary services to seniors allowing them to live independently.
  • In-Home Care Services: Direct care provided in participants' homes, encompassing skilled nursing, unskilled assistance, and personal care.
  • In-Center Services: A variety of medical, therapeutic, nutritional, and social services delivered at dedicated PACE centers.
  • Transportation Services: Coordinated transportation for participants to attend appointments at PACE centers and other third-party medical facilities.
  • Care Management: Professional oversight and coordination of all aspects of a participant's individualized care plan.

AI Analysis | Feedback

InnovAge (INNV) primarily sells its services directly to individuals. The company manages and provides a range of medical and ancillary services for seniors in need of care and support to live independently in their homes and communities through the Program of All-Inclusive Care for the Elderly (PACE) approach.

The categories of customers it serves are:

  1. Seniors and Elderly Individuals: The company's core mission is to serve older adults who require comprehensive care and support to maintain their independence and live in their homes and communities.
  2. Participants in the Program of All-Inclusive Care for the Elderly (PACE): InnovAge's customer base consists of individuals enrolled in the PACE program. These participants are typically 55 years or older, certified by their state to need nursing home-level care, and able to live safely in the community with PACE services. The company serves approximately 6,850 PACE participants.

AI Analysis | Feedback

null

AI Analysis | Feedback

Patrick Blair, Chief Executive Officer

Patrick Blair was appointed CEO of InnovAge in January 2022. He has a tenure of over four years with the company.

Ben Adams, Chief Financial Officer

Ben Adams joined InnovAge as Chief Financial Officer in July 2023. He previously served as CFO of Kepro, a physician-led, technology-enabled company, and RxSense, LLC. Earlier in his career, Adams spent over two decades as a senior healthcare investment banker.

Christine Bent, Chief Operations Officer

Christine Bent was named Chief Operations Officer of InnovAge in March 2023. Prior to joining InnovAge, she was Senior Vice President and COO at Prime Therapeutics LLC, a privately held pharmacy benefit manager. She also held clinical and operations leadership roles at Allina Health for 12 years, and leadership positions at Atrius Health and Partners Community Healthcare.

Paul Taheri, MD, MBA, Chief Medical Officer

Dr. Paul Taheri was appointed Chief Medical Officer of InnovAge in November 2025. He previously served as Clinical Quality Advisor to Welsh, Carson, Anderson & Stowe (WCAS), a private equity firm that is a major shareholder in InnovAge. Dr. Taheri's prior experience includes roles as CEO and Deputy Dean for Clinical Affairs at Yale School of Medicine, and President and CEO of the University of Vermont Medical Group.

Nicole D'Amato, Chief Legal Officer & Corporate Secretary

Nicole D'Amato has served as InnovAge's Chief Legal Officer and Corporate Secretary since July 2021. Before InnovAge, she was Senior Vice President at MacAndrews & Forbes, a company that owned a majority stake in Revlon, Inc. and was a major shareholder of Scientific Games, among other private companies. She also held senior legal roles at DIAGEO North America, Inc. and Samsonite, LLC, where she was involved in Samsonite's initial public offering on the Hong Kong Stock Exchange.

AI Analysis | Feedback

```html

Key Risks to InnovAge (INNV)

  1. Regulatory Scrutiny and Dependence on Government Payors: InnovAge operates under the Program of All-Inclusive Care for the Elderly (PACE) model, making its revenue highly dependent on government payors like Medicare and Medicaid. This exposes the company to significant regulatory risks, including audits, policy changes, and potential sanctions for non-compliance. InnovAge has previously faced enrollment suspensions and citations for care deficiencies from the Centers for Medicare & Medicaid Services (CMS) and state regulators, directly impacting its ability to enroll new participants and grow its business.
  2. Cost Management Challenges within a Capitated Model: As a PACE provider, InnovAge assumes 100% of the healthcare costs for its participants under a capitated payment model. While this model aims to incentivize preventive care and cost reduction, there is a substantial risk that the cost of providing comprehensive services, especially to its high-acuity population with an average of ten chronic conditions, could exceed the fixed compensation received. Challenges in managing these costs effectively, coupled with rising care expenses and losses from new centers, could hinder the company's path to consistent profitability.
  3. Staffing Shortages and Maintaining Quality of Care: InnovAge faces challenges related to workforce shortages in the healthcare sector, particularly for geriatric and primary care. Current and former employees have cited understaffing, high caseloads, and organizational dysfunction leading to delayed or inadequate care for participants. Such issues directly impact the quality of care provided, patient satisfaction, and can lead to regulatory actions and reputational damage, all of which are critical for the long-term success of a healthcare service provider.
```

AI Analysis | Feedback

The increasing trend among Medicare Advantage (MA) plans to offer comprehensive supplemental benefits, including in-home support, transportation, meal delivery, and enhanced care coordination, which directly overlap with and provide an alternative to the all-inclusive services offered by the Program of All-Inclusive Care for the Elderly (PACE) model.

AI Analysis | Feedback

The total addressable market for InnovAge's main product and service, the Program of All-Inclusive Care for the Elderly (PACE), is estimated to be $260 billion in the United States.

This market size is based on an estimated 2.3 million PACE-eligible individuals in the U.S. as of 2023. InnovAge targets frail, high-cost seniors who are dually eligible for Medicare and Medicaid and meet nursing home eligibility criteria. Currently, only a small fraction of these eligible individuals are enrolled in PACE programs, with approximately 77,000 participants as of June 2024.

AI Analysis | Feedback

InnovAge Holding Corp. (INNV) is expected to drive future revenue growth over the next two to three years through several key strategies:

  1. Participant Growth (Census Growth): InnovAge consistently emphasizes increasing its participant base within its Program of All-Inclusive Care for the Elderly (PACE). The company reported serving approximately 8,010 participants across 20 centers as of December 31, 2025, marking a 7.1% growth compared to the second quarter of fiscal year 2025. InnovAge's fiscal year 2026 guidance projects an ending census of 7,900 to 8,100 participants.
  2. Increased Capitation Rates: A significant portion of InnovAge's revenue is derived from capitation rates, which include annual adjustments from Medicaid and Medicare. Increases in these capitation rates directly contribute to revenue growth.
  3. Expansion of De Novo Centers: InnovAge is actively expanding its footprint by opening new "de novo" centers, such as those in Florida. While these new centers initially incur losses during their ramp-up phase, they are anticipated to become substantial contributors to revenue as they mature and increase participant enrollment.
  4. Successful Medicaid Reinstatements: The company has seen revenue growth driven by its success in reinstating participants who had previously lost Medicaid coverage. This initiative directly contributes to census growth and, consequently, revenue.
  5. Operational Efficiencies and Revenue Integrity: InnovAge is improving its revenue through enhanced revenue integrity processes, including a reduction in revenue write-offs and a strengthened Medicaid eligibility tracking system. These operational improvements ensure the company effectively captures the revenue it is entitled to, thereby contributing to overall revenue growth and profitability.

AI Analysis | Feedback

Share Repurchases

  • InnovAge reported a repurchase of equity securities totaling approximately $5.912 million in a period within fiscal year 2025.

Share Issuance

  • InnovAge completed its Initial Public Offering (IPO) in March 2021, issuing 16,666,667 shares of common stock at a price of $21.00 per share, raising approximately $350.07 million in gross proceeds.
  • Including a partial exercise of the underwriters' option to purchase additional shares, the IPO ultimately involved 18,995,901 shares, generating approximately $399 million in gross proceeds.

Inbound Investments

  • Prior to its IPO, InnovAge was a portfolio company backed by private equity firms Apax Partners LLP and Welsh, Carson, Anderson and Stowe LP.

Capital Expenditures

  • For the second quarter of fiscal year 2026 (ended December 31, 2025), InnovAge incurred $2.4 million in capital expenditures.
  • The company anticipates requiring significant capital expenditures to grow and evolve its operational and financial operations, including ensuring personnel licensing and training.
  • InnovAge's investments aim to improve health outcomes and reduce medical costs for participants, with long-term plans to reinvest savings back into the InnovAge Platform.

Better Bets vs. InnovAge (INNV)

Trade Ideas

Select ideas related to INNV.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
GEHC_4302026_Dip_Buyer_FCFYield04302026GEHCGE HealthCare TechnologiesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
IQV_4302026_Dip_Buyer_FCFYield04302026IQVIQVIADip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
UHS_4302026_Dip_Buyer_FCFYield04302026UHSUniversal Health ServicesDip BuyDB | FCFY OPMDip Buy with High FCF Yield and High Margin
Buying dips for companies with high FCF yield and meaningfully high operating margin
0.0%0.0%0.0%
ABT_4302026_Dip_Buyer_ValueBuy04302026ABTAbbott LaboratoriesDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin
0.0%0.0%0.0%
ZBIO_4302026_Insider_Buying_45D_2Buy_200K04302026ZBIOZenas BioPharmaInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
0.0%0.0%0.0%
INNV_3312021_Insider_Buying_45D_2Buy_200K03312021INNVInnovAgeInsiderInsider Buys 45DStrong Insider Buying
Companies with multiple insider buys in the last 45 days
-75.1%-75.1%-84.1%

Recent Active Movers

Peer Comparisons

Peers to compare with:

Financials

INNVACHCHCATHCENSGUHSMedian
NameInnovAge Acadia H.HCA Heal.Tenet He.Ensign Universa. 
Mkt Price7.2023.18394.07173.78171.94157.80164.87
Mkt Cap1.02.188.115.19.99.69.8
Rev LTM9493,37176,38821,8685,27417,76011,517
Op Inc LTM-439311,9733,8334492,0421,245
FCF LTM42-2927,9273,349216883550
FCF 3Y Avg8-3186,1022,172200843522
CFO LTM5218212,9994,3665921,9061,249
CFO 3Y Avg1824710,9313,0514471,7701,108

Growth & Margins

INNVACHCHCATHCENSGUHSMedian
NameInnovAge Acadia H.HCA Heal.Tenet He.Ensign Universa. 
Rev Chg LTM14.1%6.8%6.7%6.5%19.2%10.4%8.6%
Rev Chg 3Y Avg11.6%7.7%7.9%4.1%18.2%9.4%8.6%
Rev Chg Q15.5%7.6%4.3%10.7%18.4%9.6%10.2%
QoQ Delta Rev Chg LTM3.7%1.8%1.0%2.6%4.3%2.3%2.4%
Op Inc Chg LTM81.4%-16.6%10.4%25.2%18.9%16.8%17.9%
Op Inc Chg 3Y Avg47.3%-5.8%8.9%18.0%16.5%25.1%17.2%
Op Mgn LTM-0.5%11.7%15.7%17.5%8.5%11.5%11.6%
Op Mgn 3Y Avg-2.4%14.8%15.1%15.0%8.0%10.4%12.6%
QoQ Delta Op Mgn LTM-2.0%-0.0%-0.2%1.4%0.1%0.0%-0.0%
CFO/Rev LTM5.5%5.4%17.0%20.0%11.2%10.7%11.0%
CFO/Rev 3Y Avg1.7%7.8%15.2%14.4%9.8%10.9%10.3%
FCF/Rev LTM4.5%-8.7%10.4%15.3%4.1%5.0%4.7%
FCF/Rev 3Y Avg0.6%-10.1%8.5%10.2%4.5%5.2%4.9%

Valuation

INNVACHCHCATHCENSGUHSMedian
NameInnovAge Acadia H.HCA Heal.Tenet He.Ensign Universa. 
Mkt Cap1.02.188.115.19.99.69.8
P/S1.00.61.20.71.90.50.9
P/Op Inc-219.45.37.43.922.14.75.0
P/EBIT-105.9-2.37.33.820.54.44.1
P/E-84.2-1.913.08.927.36.37.6
P/CFO18.611.56.83.516.85.19.2
Total Yield-1.2%-52.8%8.5%11.3%3.8%16.3%6.1%
Dividend Yield0.0%0.0%0.8%0.0%0.1%0.5%0.1%
FCF Yield 3Y Avg0.7%-9.6%6.5%16.1%2.4%7.2%4.4%
D/E0.11.30.60.90.20.50.5
Net D/E-0.01.20.60.70.20.50.5

Returns

INNVACHCHCATHCENSGUHSMedian
NameInnovAge Acadia H.HCA Heal.Tenet He.Ensign Universa. 
1M Rtn-5.9%-17.2%-16.4%-9.1%-7.7%-12.7%-10.9%
3M Rtn-11.8%38.1%-25.9%-24.4%-18.3%-31.5%-21.4%
6M Rtn37.1%52.7%-19.5%-9.5%-7.0%-31.8%-8.2%
12M Rtn79.1%1.0%5.3%7.7%19.0%-15.1%6.5%
3Y Rtn4.5%-66.4%50.7%150.2%88.5%26.0%38.3%
1M Excs Rtn-12.1%-20.4%-22.0%-12.9%-14.3%-18.0%-16.2%
3M Excs Rtn-28.6%24.1%-35.7%-35.0%-29.0%-41.4%-32.0%
6M Excs Rtn30.6%49.1%-30.4%-23.1%-16.2%-43.2%-19.6%
12M Excs Rtn47.7%-29.3%-24.0%-21.1%-10.0%-44.6%-22.6%
3Y Excs Rtn-67.0%-147.4%-33.3%60.9%9.7%-60.7%-47.0%

Comparison Analyses

null

Financials

Segment Financials

Revenue by Segment
$ Mil20252024202320222021
Program of All-Inclusive Care for the Elderly (PACE)763687697636565
All other11122
Total764688699638567


Price Behavior

Price Behavior
Market Price$7.20 
Market Cap ($ Bil)1.0 
First Trading Date03/04/2021 
Distance from 52W High-32.1% 
   50 Days200 Days
DMA Price$7.93$6.20
DMA Trendupdown
Distance from DMA-9.2%16.2%
 3M1YR
Volatility57.8%82.9%
Downside Capture189.9890.34
Upside Capture87.68131.79
Correlation (SPY)34.5%20.6%
INNV Betas & Captures as of 4/30/2026

 1M2M3M6M1Y3Y
Beta1.611.871.350.441.551.15
Up Beta1.240.981.831.322.141.37
Down Beta0.371.231.55-0.061.220.79
Up Capture97%194%222%102%278%143%
Bmk +ve Days15223166141428
Stock +ve Days12203263128361
Down Capture766%272%44%-32%100%106%
Bmk -ve Days4183056108321
Stock -ve Days9223057113364

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with INNV
INNV75.2%82.9%1.02-
Sector ETF (XLV)16.0%14.5%0.8031.7%
Equity (SPY)29.5%12.0%1.8620.4%
Gold (GLD)35.5%26.8%1.1110.6%
Commodities (DBC)42.9%18.7%1.77-1.9%
Real Estate (VNQ)15.2%13.1%0.8232.5%
Bitcoin (BTCUSD)-29.5%41.7%-0.7310.5%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with INNV
INNV-19.2%74.3%0.04-
Sector ETF (XLV)5.7%14.7%0.2125.4%
Equity (SPY)14.0%17.0%0.6427.1%
Gold (GLD)18.8%18.0%0.858.4%
Commodities (DBC)10.4%19.4%0.423.1%
Real Estate (VNQ)3.8%18.8%0.1028.9%
Bitcoin (BTCUSD)12.2%55.3%0.4213.0%

Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
Annualized
Return
Annualized
Volatility
Sharpe
Ratio
Correlation
with INNV
INNV-11.5%73.4%0.00-
Sector ETF (XLV)9.9%16.5%0.4925.3%
Equity (SPY)15.7%17.9%0.7527.0%
Gold (GLD)13.0%16.0%0.678.4%
Commodities (DBC)7.8%17.9%0.353.2%
Real Estate (VNQ)5.5%20.7%0.2328.3%
Bitcoin (BTCUSD)67.2%66.9%1.0613.3%

Smart multi-asset allocation framework can stack odds in your favor. Learn How

Short Interest

Short Interest: As Of Date4302026
Short Interest: Shares Quantity0.8 Mil
Short Interest: % Change Since 415202620.5%
Average Daily Volume0.2 Mil
Days-to-Cover Short Interest4.2 days
Basic Shares Quantity135.7 Mil
Short % of Basic Shares0.6%

Earnings Returns History

Expand for More
 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
5/5/20262.0%-5.2% 
2/3/202637.5%47.9%68.4%
9/9/2025-2.8%21.3%36.8%
5/6/202514.4%38.9%39.3%
2/4/2025-9.1%-8.9%-6.8%
9/10/2024-6.5%-3.7%-8.3%
5/7/20240.0%-5.6%13.4%
2/6/2024-3.9%-3.0%-8.1%
...
SUMMARY STATS   
# Positive887
# Negative888
Median Positive4.1%14.7%25.0%
Median Negative-6.6%-7.3%-9.6%
Max Positive37.5%52.3%68.4%
Max Negative-24.9%-41.8%-43.9%

SEC Filings

Expand for More
Report DateFiling DateFiling
03/31/202605/08/202610-Q
12/31/202502/03/202610-Q
09/30/202511/04/202510-Q
06/30/202509/09/202510-K
03/31/202505/06/202510-Q
12/31/202402/04/202510-Q
09/30/202411/05/202410-Q
06/30/202409/10/202410-K
03/31/202405/07/202410-Q
12/31/202302/06/202410-Q
09/30/202311/07/202310-Q
06/30/202309/12/202310-K
03/31/202305/09/202310-Q
12/31/202202/07/202310-Q
09/30/202211/08/202210-Q
06/30/202209/13/202210-K

Recent Forward Guidance [BETA]

Latest: Q3 2026 Earnings Reported 5/5/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Census7,9008,0008,1000 AffirmedGuidance: 8,000 for 2026
2026 Total Member Months92,90094,30095,7000 AffirmedGuidance: 94,300 for 2026
2026 Revenue950.00 Mil962.50 Mil975.00 Mil2.7% RaisedGuidance: 937.50 Mil for 2026
2026 Adjusted EBITDA85.00 Mil87.50 Mil90.00 Mil20.7% RaisedGuidance: 72.50 Mil for 2026

Prior: Q2 2026 Earnings Reported 2/3/2026

Forward GuidanceGuidance Change
MetricLowMidHigh% Chg% DeltaChangePrior
2026 Census7,9008,0008,1000 AffirmedGuidance: 8,000 for 2026
2026 Total Member Months92,90094,30095,7001.4% RaisedGuidance: 93,000 for 2026
2026 Revenue925.00 Mil937.50 Mil950.00 Mil1.4% RaisedGuidance: 925.00 Mil for 2026
2026 Adjusted EBITDA70.00 Mil72.50 Mil75.00 Mil19.8% RaisedGuidance: 60.50 Mil for 2026

Insider Activity

Expand for More
#OwnerTitleHoldingActionFiling DatePriceSharesTransacted
Value
Value of
Held Shares
Form
1Scarbrough, Michael AnthonyPresident and COODirectSell111720254.9033,000161,700586,123Form
2Zoretic, Richard C DirectBuy53020254.088,45034,476279,456Form
3Zoretic, Richard C DirectBuy53020254.0414,26557,631242,578Form
4Zoretic, Richard C DirectBuy53020254.0620,00081,200185,863Form
5Zoretic, Richard C DirectBuy52320253.931,1984,708101,311Form